Opioids and immune modulation: More questions than answers

British Journal of Anaesthesia

Volumn 111, Issue 1, 2013, Pages 80-88

  Al Hashimi, M ^a   Scott, S W M ^a   Thompson, J P ^a   Lambert, D G ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

HPA axis; immunomodulation; opioid receptors

Indexed keywords

CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DELTA OPIATE RECEPTOR; GLUCOCORTICOID; HYDROCORTISONE; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; NOCICEPTIN; NOCICEPTIN RECEPTOR; OPIATE DERIVATIVE;

ADENOHYPOPHYSIS; ADRENAL CORTEX; ANTIGEN ANTIBODY REACTION; BLOOD BRAIN BARRIER; CORTICOTROPIN RELEASE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATION; NONHUMAN; NUTRITIONAL STATUS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SEPSIS;

EID: 84880195172     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aet153     Document Type: Article

References (87)

1. Risdahl JM, Khanna KV, Peterson PK, Molitor TW. Opiates and infection. J Immunol 1998; 83: 4-18
2. Hussey HH, Katz S. Infections resulting from narcotic addiction; report of cases. Am J Med 1950; 9: 186-93
3. Nincovi J, Roy S. Role of the mu-opioid receptors in opioid modulation ofimmunefunction.AminoAcidsAdvanceAccess published on Dec 15, 2011, doi: 10.1007/s00726-011-1163-0
4. Byrant HU, Bernton EW, Holaday JW. Morphine pellet induced immunomodulation in mice: temporal relationships. J Pharmacol Exp Ther 1988; 245: 913-20
5. Byrant HU, Yoburn BC, Inturrisi CE, Bernton EW, Holaday JW. Morphine-induced immunomodulation is not related to serum morphine concentration. Eur J Pharmacol 1988; 149: 165-9
6. Byrant HU, Bernton EW, Kenner JR, Holaday JW. Role of adrenal cortical activation in the immunosuppressive effect of chronic morphine treatment. Endocrinology 1991; 128: 3253-8
7. Roy S, Balasubramanian S, Sumandeep S, et al. Morphine directs T cells toward T(H2) differentiation. Surgery 2001; 130: 304-9
8. Gaveriaux-Ruff C, Matthes HW, Peluso J, Kieffer BL. Abolition of morphine-immunosuppression in mice lacking the mu-opioid receptor gene. Proc Natl Acad Sci USA 1998; 95: 6326-30
9. Bussiere JL, AdlerMW, Rogers TJ, Eisenstein TK. Cytokine reversal of morphine-induced suppression of the antibody response. J Pharmacol Exp Ther 1993; 264: 591-7
10. Bhargava HN, Thomas PT, Thorat S, House RV. Effects of morphine tolerance and abstinence on cellular immune function. Brain Res 1994; 642: 1-10
11. Bussiere JL, AdlerMW, Rogers TJ, Eisentein TK. Differential effect of morphine and naltrexone on the antibody response in various mouse strains. Immunopharmacol Immunotoxicol 1992; 14: 657-73
12. Pacifici R, Di Carlo S, Bacosi A, Pichini S, Zuccaro P. Pharmacokinetics and cytokine production in heroin and morphine-treated mice. Int J Immunopharmacol 2000; 22: 603-14
13. Wang J, Barke RA, Charboneau R, Loh HH, Roy S. Morphine negatively regulates interferon-gamma promoter activity in activated murine T cells through two distinct cyclic AMP-dependent pathways. J Biol Chem 2003; 278: 37622-31
14. Borner C, Kraus J, Bedini A, Schraven B, Hollt V. T-cell receptor/ CD28-mediated activation of human T lymphocytes induced expression of functional mu-opioid receptors. Mol Pharmacol 2008; 74: 496-504
15. Roy S, Wang J, Kelschenbech J, Koodie L, Martin J. Modulation of immune function by morphine: implications for susceptibility to infection. J Neuro Immune Pharmacol 2006; 1: 77-89
16. Casellas AM, Guardiola H, Renaud FL. Inhibition by opioids of phagocytosis in peritoneal macrophages. Neuropeptides 1991; 18: 35-40
17. Perez-Castrillon JL, Perez-Arellano JL, Garcia-Palomo JD, Jimenez-Lopez A, De Castro S. Opioids depress in vitro human monocyte chemotaxis. Immunopharmacol 1992; 23: 57-61
18. Szebo I, Rojavin M, Bussiere JL, Eisenstein TK, Adler MW, Rogers TJ. Suppression of peritoneal macrophage phagocytosis of Candida albicans by opioids. J Pharmacol Exp 1993; 267: 703-6
19. Sharp BM, Keane WF, Suh HJ, Gekker G, Tsukayama D, Peterson PK. Opioid peptides rapidly stimulate superoxide production byhuman polymorphonuclear leukocytes and macrophages. Endocrinology 1985; 117: 793-5
20. Simpkins CO, Alailima ST, Tate EA, Johnson M. The effect of enkephalins and prostaglandins on O-2 release by neutrophils. J Surg Res 1986; 41: 645-52
21. Welters ID, Menzebach A, Goumon Y, et al. Morphine suppresses complement receptor expression, phagocytosis, and respiratory burst in neutrophils by nitric oxide and mu(3) opiate receptordependent mechanisms. J Neuroimmunol 2000; 111: 139-45
22. Grimm MC, Ben-Baruch A, Taub DD, Howard OM, Wang JM, Oppenheim JJ. Opiate inhibition of chemokine induced chemotaxis. Ann NY Acad Sci 1998; 840: 9-20
23. Simpkins CO, Dickey CA, Fink MP. Human neutrophil migration is enhanced by beta-endorphin. Life Sci 1984; 34: 2251-5
24. Martin JL, Koodie L, Krishnan AG, Charboneau R, Barke RA, Roy S. Chronic morphine administration delays wound healing by inhibiting immune cell recruitment to the wound site. Am J Pathol 2010; 176: 786-99
25. Frenklakh L, Bhat RS, Bhaskaran M, Sharma S, Sharma M, Dinda A. Morphine-induced degradation of the host defence barrier role of intestinal mucosal injury. Dig Dis Sci 2006; 51: 318-25
26. Min TJ, Kim JH, Noh KH, Kim TW, Kim WY. Morphine postconditioning attenuates ICAM-1 expression on endothelial cells. J Korean Med Sci 2011; 26: 290-6
27. Chang MC, Fan SZ, Hsiao PN, Cheng WF, Sun WZ. Influence of morphine on host immunity. Acta Anaesthesiol Taiwan 2011; 46: 105-8
28. Vuong C, Uum SHMV, O'Dell LE, Lutfy K, Friedman TC. The effects of opioids and opioid analogues on animal and human endocrine systems. Endocr Rev 2010; 31: 98-132
29. Hoffmann GW. The 'Intelligence' of Antigen-specific Receptors from a Network Point of View. In: Sercarz E, Cunningham AJ, eds. The Strategy of Immune Regulation. New York, NY: Academic Press, 1980; 401-40
30. Erb P. What is immunoregulation? Agents Actions 1984; 15: 59-61
31. Pert CB, Snyder SH. Opiate receptor: demonstration in nervous tissue. Science 1973; 179: 1011-4
32. Lord JA, Waterfield AA, Hughes J, Kosterlitz HW. Endogenous opioid peptides: multiple agonists and receptors. Nature 1977; 267: 495-9
33. Olson GA, Olson RD, Kastin AJ. Endogenous opiates: 1992. Peptides 1993; 14: 1339-78
34. Zadina JE, Hackler L, Ge LJ, Kastin AJ. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 1997; 386: 499-502
35. Kieffer BL, Befort K, Gaveriaux-Ruff C, Hirth CG. The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci USA 1992; 89: 12048-52
36. Evans CJ, Keith DE, Morrison H, Magendzo K, Edwards RH. Cloning of a delta opioid receptor by functional expression. Science 1992; 258: 1952-5
37. Granier S, Manglik A, KruseAC, et al. Structure of the d-opioid receptor bound to naltrindole. Nature 2012; 485: 400-4
38. Thompson AA, Liu W, Chun E, et al. Structure of the nociceptin/ orphanin FQ receptor in complex with a peptide mimetic. Nature 2012; 485: 395-9
39. Wu H,Wacker D, Mileni M, et al. Structure of the human k-opioid receptor in complex with JDTic. Nature 2012; 485: 327-32
40. Manglik A, Kruse AC, Kobilka TS, et al. Crystal structure of the m-opioid receptor bound to a morphine antagonist. Nature 2012; 485: 321-6
41. Dietis N, Rowbotham DJ, Lambert DG. Opioid receptor subtypes: fact or artefact? Br J Anaesth 2011; 107: 8-18
42. Lambert DG. The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential. Nat Rev Drug Discov 2008; 7: 694-710
43. Dietis N, Guerrini R, Calo G, Salvadori S, Rowbotham DJ, Lambert DG. Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth 2009; 103: 38-49
44. Sacerdote P. Opioids and the immune system. Palliat Med 2006; 20: s9-15
45. The British Pain Society's opioids for persistent pain: Good practice. 2010. Available from http://www.britishpainsociety.org/book- opioid-main.pdf (accessed 30 January 2013)
46. Sacerdote P, Limiroli E, Gaspani L. Experimental evidence for immunomodulatory effects of opioids. Adv Exp Med Biol 2003; 521: 106-16
47. Sacerdote P, Manfredi B, Mantegazza P. Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. Br J Pharmacol 1997; 121: 834-40
48. Jacobs R, Karst M, Scheininchen D. Effects of fentanyl on cellular immunefunction I man.Int JImmunopharmacol 1999;21: 445-54
49. Odunayo A, Dodam JR, Kerl ME, DeClue AE. Immunomodulatory effects of opioids. J Vet Emerg Crit Care 2010; 20: 376-85
50. Roy S, Barker RA, Loh HH. Mu-opioid receptor-knockoutmice: role ofmu-opioid receptors inmorphinemediated immune receptors in morphine mediated immune function. Brain Res 1998; 61: 190-4
51. Nelson CJ, Schneider GM, Lysle DT. Involvement of central mu- but not delta- or kappa-opioid receptors in immunomodulation. Brain Behav Immun 2000; 14: 170-84
52. Hernandez M, Flores L, BayerB.Immunosuppression bymorphine is mediated by central pathways. J Pharmacol Exp Ther 1993; 267: 1336-41
53. Shavit Y, Depaulis A, Martin FC. Involvement of brain opiate receptors in the immune-suppressive effect of morphine. Proc Natl Acad Sci USA 1986; 83: 7114-7
54. Hall DM, Suo JL,Weber RJ. Opioid mediated effects on the immune system: sympathetic nervous systeminvolvement. J Neuroimmunol 1998; 83: 29-35
55. Vallejo R, De Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a review. Am J Ther 2004; 11: 354-65
56. Bidlack JM. Detection and function of opioid receptors on cells from the immune system. Clin Diag Lab Immunol 2000; 7: 719-23
57. Cedat P, Mantione K, Bilfinger TV, Stefano GB. Real-time PT-PCR measurement of the modulation of Mu opioid receptor expression by nitric oxide in human mononuclear cells. J Immunol 2001; 170: 1123-8
58. Calderioli E, Leoni O, Cattaneo S, Rasini E, MarinoV. Neutrophil function and opioid receptor expression on leucocytes during chronic naltrexone treatment in humans. Pharmacol Res 1999; 20: 153-8
59. Chuang TK, Killam KF, Chuang LF, Kung HF, Sheng WS. MuOpioid receptor gene expression in immune cells. Biochem Biophys Res Commun 1995; 216: 922-30
60. Mehrishi JN, Mills IH. Opiate receptors on Lymphocytes and platelets in man. Clin Immunol Immunopathol 1983; 27: 240-9
61. Beck M, Mirmohammadasdegh A, Franz B, Blanke J, Hengge UR. Opioid receptors on white blood cells: effect of HIV infection and methadone treatment. Pain 2002; 98: 187-94
62. Suzuki S, Miyagi T, Chuang TK, Chuang LF, Doi RH, Chuang RY. Morphine upregulatesmuopioid receptors of humanand monkey lymphocytes. Biochem Biophys Res Commun 2000; 279: 621-8
63. Williams JP, Thompson JP, McDonald J, et al. Human peripheral blood mononuclear cells express nociception/orphanin FQ, but not mu, delta, or kappa opioid receptors. Anaesth Analg 2007; 105: 998-1005, table of contents
64. Williams JP. OpioidsandaNeuro-Vascular-Immuneaxis. University of Leicester doctoral thesis 2008. Available from http://hdl.handle .net/2381/4160 (accessed 4 February 2013)
65. Al-Hashimi M, McDonald J, Thompson JP, Lambert DG. Classical opioid receptormRNAisNOTpresent inwholehumanblood.Anaesthetic Research Society Winter Scientific Meeting. Abstract presentation booklet. Br J Anaesth in press
66. CastroM, Elias LL, Elias PCL, MorieiraAC.Physiologyandpathophysiology of the HPA axis. Cushing's Syndr Contemp Endocrinol 2011; 1-20
67. Franchimont D. Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. Ann NY Acad Sci 2004; 1024: 124-37
68. Facchinetti F, Grasso A, Petraglia F, Parrini D, Volpe A, Genazzani AR. Impaired circadian rhythmicity of beta-lipotrophin, betaendorphin and ACTH in heroin addicts. Acta Endocrinol (Copenh) 1984; 105: 149-55
69. Serrano-Gomez A, Thompson JP, Lambert DG. Nociceptin/orphanin FQ in inflammation and sepsis. Br J Anaesth 2011; 106: 6-12
70. Stamer UM, Book M, Comos C, Zhang L, Nauck F, Stuber F. Expression of the nociceptin precursor and nociceptin receptor is modulated in cancer and septic patients. Br J Anaesth 2011; 106: 566-72
71. Williams JP, Thompson JP, Young SP, et al. Nociceptin and urotensin-II concentrations in critically ill patients with sepsis. Br J Anaesth 2008; 100: 810-4
72. AntonB, Leff P, Meissler JJ, et al. Nociceptin/orphaninFQsuppresses adaptive immune responses in vivo and at picomolar levels in vitro. J Neuroimmune Pharmacol 2010; 5: 143-54
73. Alt C, LamJS, Harrison MT, et al. Nociceptin/orphanin FQ inhibition with SB612111 ameliorates dextran sodium sulfate-induced colitis. Eur J Pharmacol 2012; 683: 285-93
74. Williams JP, Thompson JP, Rowbotham DJ, Lambert DG. Human peripheral blood mononuclear cells produce pre-pro-nociceptin/ orphanin FQ mRNA. Anesth Analg 2008; 106: 865-6, table of contents
75. McDonald J,Howells L, Brown K,ThompsonJ, Lambert D. Use of preparative fluorescence activated cell sorting (FACS) to profile opioid receptor and peptide mRNA expression on human granulocytes, lymphocytes and monocytes. Br J Anaesth 2010; 105: 707
76. Fiset ME, Gilbert C, Poubelle PE, Pouliot M. Human neutrophils as a source of nociceptin: a novel link between pain and inflammation. Biochemistry (Mosc) 2003; 42: 10498-505
77. Serhan CN, Fierro IM, Chiang N, Pouliot M. Cutting edge: nociceptin stimulates neutrophil chemotaxis and recruitment: inhibition by aspirin-triggered-15-epi-lipoxin A4. J Immunol 2001; 166: 3650-4
78. Trombella S, Vergura R, Falzarano S, Guerrini R, Calo G, Spisani S. Nociceptin/orphanin FQ stimulates human monocyte chemotaxis via NOP receptor activation. Peptides 2005; 26: 1497-502
79. Donica C, Ramirez V,AwwadH, Zaveri N, Toll L, Standifer K. Orphanin FQ/nociceptin activates nuclear factor kappa B. J Neuroimmune Pharmacol 2011; 6: 617-25
80. Schultz JJ, Hsu AK, Gross GJ. Ischemic preconditioning and morphine-induced cardioprotection involve the delta (delta)- opioid receptor in the intact rat heart. J Mol Cell Cardiol 1977; 29: 2187-95
81. Cao Z, Liu I, VanWinkle DM. Activation of delta- and kappaopioid receptors by opioid peptides protects cardiomyocytes via KATP channels. Am J Physiol Heart Circ Physiol 2003; 285: 1032-9
82. Pepe S, van den Brink OW, Lakatta EG, Xiao RP. Cross-talk of opioid peptide receptor and beta-adrenergic receptors signalling in the heart. Cardiovasc Res 2004; 179: 1011-4
83. Felten DL, FeltenSY, Carlson SL, Olschowka JA, Livnat S. Noradrenergic and peptidergic innervation of lymphoid tissue. J Immunol 1985; 135: 755-65
84. Abrass CK, O'ConnorSW, Scarpace PJ, Abrass IB. Characterization of the b-adrenergic receptor of the rat peritoneal macrophages. J Immunol 1985; 138: 1338
85. Spengler RN, Allen RM, Remick DG, Strieter RM, Kunkel SL. Stimulation of a-adrenergic receptor augments the production of macrophage-derived tumour necrotic factor. J Immunol 1990; 145: 1430
86. Sanders VM, Munson AE. Role of alpha adrenergic activation in modulating the murine primary antibody response in vitro. J Pharmacol Exp Ther 1985; 232: 395-400
87. Fecho K, Maslonek KA, Dykstra LA, Lysla DT. Alterations of immune status induced by thesympathetic nervous system:immunomodulatory effects of DMPP alone and in combination with morphine. Brain Behav Immun 1993; 7: 253-70